ECOR electroCore, Inc. logo

ECOR electroCore, Inc.

Healthcare
$6.67+11.35%ClosedMarket Cap: $55.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

-10.50

P/S

1.59

EV/EBITDA

-4.49

DCF Value

$-403.81

FCF Yield

-12.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

87.2%

Operating Margin

-42.0%

Net Margin

-44.1%

ROE

836.3%

ROA

-99.4%

ROIC

-379.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$9.6M$-5.3M$
Q4 null$9.2M$-3.0M$
FY null$32.0M$-14.0M$
Q3 null$8.7M$-3.4M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-01-26

Trading Activity

Insider Trades

View All
Lev Joshua S.officer: CFO and Interim President
SellFri May 22
Goldberger Daniel Sother: Former Officer and Director
SellTue Apr 14
Fox Michaelofficer: Chief Operating Officer
SellTue Apr 14
Fox Michaelofficer
SellTue Apr 14
Lev Joshua S.officer: CFO and Interim President
SellWed Apr 01

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.68

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Peers